Miso Therapeutics: Targeting cancer cells' Metabolic isoenzyme addiction: Triple-negative breast cancer (TNBC) lacks targeted therapies and therefore rely on chemotherapy with its associated side effects. TNBC is an aggressive disease with high metabolic rewiring. We have identified PCK2 as a TNBC-specific metabolic target by comparing RNA sequencing data from patient-matched clinical samples. PCK2 is a novel target and lacks an inhibitor, a protein model, and an enzyme assay. To this end, we have created a homology model, a high throughput enzyme assay, and identified an active hit. Using the Blavatnik fund, we propose to perform lead optimization, PK/PD, and in vivo validation.
Favorite Off-Time Activity
A like to read books. Reading about topics unrelated to medicine and cancer research that unclutter my mind and enriches me with ideas that I sometimes can bring back to my day job, medical oncology and breast cancer research. Right now I am reading books about the life of Albrehct Durer, the history of Islam, and how the Este Lauder cosmetics company was funded. I also like hiking, running, bicycling, see kayaking, skiing, sailing with my sons. The interesting thing about being alone in nature is that I never feel lonely, unlike being alone in a restaurant or in a crowded space.
Best Advice for new entrepreneurs
An idea is a good start, but your team is everything and failure is the foundation of future success.
